Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for multidisciplinary national conferences that will inform care and facilitate research for major issues in pediatric critical care medicine. Given the nascent stage of development, the small diverse patient populations, and the rapid expansion of the field, conducting research and establishing best practices in pediatric critical care is challenging. National conferences that convene experts from across the country hold the potential to establish the frameworks necessary to overcome these obstacles. It is anticipated that such conferences will foster collaboration among different clinical disciplines, geographically and culturally diverse institutions and medical centers, professional organizations and NIH Institutes. Specifically, it is hoped that these conferences will drive the development and acceptance of uniform definitions, facilitate the determination of common data elements, identify key knowledge gaps to advance research, and/or foster discussions on how research findings can be used to best inform guidelines for patient care.

Encourages new investigators by providing seed and start-up funding for promising research projects that address issues related to the treatment of arthritis with an emphasis on arthroplasty. Clinical relevance must be clearly noted in the abstract and specific aims, and be obvious from the title and the study design. All proposed projects should generate results that have a practical application. It is expected that upon completion of the proposed project, the principal investigator will be well poised to pursue NIH/DOD or the equivalent large-scale funding to continue to advance the area of research.

This initiative will provide two years of support for planning activities necessary for initiating a Phase III clinical trial designed to validate VCID biomarkers and/or treat patients with VCID. The full spectrum of VCID is in scope, and the one or more VCID disorders(s) to be targeted in the trial must be clearly specified in the application, for example (but not limited to): vascular insults including clinical stroke, silent infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), transient ischemic attack (TIA), micro-bleeds, CADASIL, and vascular contributions to Alzheimers dementia. Planning activities may include identifying trial sites/collaborations, designing trial protocols and procedures, and addressing regulatory approvals.

The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists.

Funding Opportunity Goals: Goal 1: Through robust partnerships, develop a result-based, comprehensive strategy for reducing falls and falls risk among older adults and adults with disabilities living in your community. Goal 2: Significantly increase the number of older adults and adults with disabilities who participate in evidence-based falls prevention programs, while concurrently pursuing the sustainability of these programs beyond the end of the grant period.

The purpose of this FOA is to solicit applications for research projects to generate reference datasets and to create navigable maps for the study of the spatial and temporal organization of the nucleus, using genomic and imaging data as well as newly developed visualization and integrative analysis tools.

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at https://www.niddk.nih.gov/about-niddk/research-areas.

Once established, type 1 diabetes (T1D) requires daily insulin administration and episodes of hyperglycemia and hypoglycemia are common. As a result, patients with T1D without adequate control may suffer devastating acute complications such as life-threatening hypoglycemia and ketoacidosis and long term complications including accelerated cardiac and peripheral vascular diseases, nephropathy, retinopathy, neuropathy, amputation and premature death. Studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have shown that long term microvascular and macrovascular complications can be reduced through tight blood glucose control. However, the increased risk of hypoglycemia that is associated with tight control and the limitations of current glucose control technologies make tight control difficult to achieve. Thus, there is a need for tools to help more people with T1D to safely achieve and sustain tight blood glucose control and reduce burden of care.

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes that occurs during or after one or more episodes of acute pancreatitis. The teams will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have impaired glucose tolerance or diabetes mellitus after one or more episodes of acute pancreatitis due to various identifiable etiologies. Applications for the Data Coordinating Center (DCC) are submitted in response to a separate FOA: RFA-DK-19-023: Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC) (U01).

The American Institute of the History of Pharmacy wishes to encourage academic research within its scope. Therefore it offers a grant-in-aid of up to $2,000 to a graduate student to reinforce historical investigations of some aspect of pharmacy, whether ancient or modern, to pay research expenses not normally met by the university granting the degree. Any dissertation project devoted to the history of pharmacy, history of drugs, or other humanistic study utilizing a pharmaco-historical approach, is eligible if based in an institution of higher learning of the USA. Applications postmarked by February 1, 2020, will be evaluated at that time. Applications thereafter will be considered individually if or when funds are available.

The Agency for Toxic Substances and Disease Registry (ATSDR) is soliciting investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the ATSDR National ALS Registry's mission. The National ALS Registry's goals are to estimate the number of new ALS cases each year, estimate the number of people who have ALS at a specific point in time, better understand who gets ALS, and identify what contributing factors, including environmental, may affect ALS. ATSDR is seeking investigator-initiated research that will identify and evaluate risk factors contributing to ALS, with preferred focus in this Notice of Funding Opportunity on factors related to military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents.

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after acute pancreatitis.. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

The Electrical, Communications and Cyber Systems Division (ECCS) supports enabling and transformative engineering research at the nano, micro, and macro scales that fuels progress in engineering system applications with high societal impact. This includes fundamental engineering research underlying advanced devices and components and their seamless penetration in power, controls, networking, communications or cyber systems. The research is envisioned to be empowered by cutting-edge computation, synthesis, evaluation, and analysis technologies and is to result in significant impact for a variety of application domains in healthcare, homeland security, disaster mitigation, telecommunications, energy, environment, transportation, manufacturing, and other systems-related areas. ECCS also supports new and emerging research areas encompassing 5G and Beyond Spectrum and Wireless Technologies, Quantum Information Science, Artificial Intelligence, Machine Learning, and Big Data.

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

This Funding Opportunity Announcement (FOA) is soliciting requests for access to dental practice-based research network (PBRN) resources for developmental/exploratory, pilot, and/or survey studies to be conducted in the to be conducted in the dental PBRN. Successful applicants will be given access to the NIDCR-funded dental PBRN infrastructure.

The overall goal of the NIH Research Career Development program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs. NIH Institutes and Centers (ICs) support a variety of mentored and non-mentored career development award programs designed to foster the transition of new investigators to research independence and to support established investigators in achieving specific objectives. Candidates should review the different career development (K) award programs to determine the best program to support their goals. More information about Career programs may be found at the NIH Extramural Training Mechanisms website. The objective of the Career Enhancement Award for Experienced Investigators (K18) is to provide support for experienced scientists who either wish to broaden their scientific capabilities or to make changes in their research careers by acquiring new research skills or knowledge. The purpose of this FOA is to provide such investigators with support for an intensive period of mentored research experience to acquire new research capabilities in research areas supported by the sponsoring NIH Institute(s)/Center(s). Such experiences will afford candidate investigators protected time to: 1) enrich and expand their expertise and research programs through retooling in new techniques, emerging technologies, and/or scientific areas; and/or 2) redirect their research programs in new trajectories; and/or 3) catalyze research collaborations in new research directions.  It is expected that this initiative will lead to new and/or augmented research programs competitive for NIH funding.

This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD.Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets.

The End TB Strategy envisions a world free of tuberculosis (TB)-zero deaths, disease and suffering due to TB by 2035. This requires reducing the global TB incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Each year, an estimated 10 million people develop TB disease, and an estimated 1.6 million TB people die from TB - the leading cause of death from any infectious disease. In 2017, 90% of all estimated new TB cases were adults (15 years of age or older), and 9% were persons living with HIV (PLHIV) with 72% living in Africa. Despite being preventable and treatable, large gaps in detection and treatment of TB cases remain; of the estimated 10 million new TB cases in 2017, only 6.4 million TB cases were officially reported.

The United States Government represented by the United States Agency for International Development in Ethiopia (USAID/Ethiopia) is seeking applications from qualified entities to implement the Eliminate Tuberculosis from Ethiopia (ETBE) Activity through a five-year Cooperative Agreement mechanism. Eligibility for this award is not restricted.